Reply to thread

Message: <blockquote data-quote="Stimulus mind" data-source="post: 26717732" data-attributes="member: 577135"><img src="https://nbcmontana.com/resources/media/c71a10b1-6e64-4f83-bb7a-01369c68e9d6-medium16x9_AP21211740469977.jpg?1628025144199" alt="" class="fr-fic fr-dii fr-draggable " style="" />Jay Vojno gets the Johnson & Johnson COVID-19 vaccine, Friday, July 30, 2021, in New York. (AP Photo/Mark Lennihan)When it comes to ivermectin, many doctors have prescribed it despite a statement released by the drug's maker Merck, that there is no scientific basis for a potential therapeutic effect of the drug against COVID-19, but there is a “concerning lack of safety data in the majority of the studies.”Ray said health care workers would “jump at an inexpensive, safe drug that treats COVID,” but there is not any credible evidence that ivermectin works for COVID. Many publications on it have been retracted, but the drug continues to be controversially promoted for use in Latin America and South Africa despite the lack of hard evidence.A number of hurdles slow the process of a clinical trial. Ray said doctors haven’t had enough trial participants in the same stage of the virus to ensure well-composed trials, considering pandemic cases lessened in February and March. Unfortunately, he said, the delta variant will allow for more comprehensive clinical trials, which could accelerate the development of an antiviral treatment, potentially in six to 12 months.The nature of COVID brings its own challenges to the table. Running a trial of patients early in the course of their disease is likely when an antiviral works best.<img src="https://nbcmontana.com/resources/media/91f2b32b-743e-45da-b282-f1a0c1869270-medium16x9_AP20296740256787.jpg?1628025612377" alt="" class="fr-fic fr-dii fr-draggable " style="" />FILE - In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. (Gilead Sciences via AP)This, of course, is difficult with a virus that doesn’t show symptoms for days. By the time patients experience symptoms, they’re five to 14 days into the illness. However, these patients are following public health messaging by staying home if they’ve been infected. Once they’re in the hospital, they likely won’t agree to a clinical trial that could possibly give them a placebo instead of a real drug.With all this being said, treatment trials are underway. Merck announced their investigational oral therapeutic molnupiravir — which mimics a block of RNA and interferes with replication, like remdesivir but in pill form — showed promising results in its phase 2/3 trial. The U.S. government has agreed to buy 1.7 million courses of it if it’s granted EUA by the FDA.However, a monetary commitment doesn’t mean the antiviral will work. Ray said one of the reasons COVID vaccines were developed and rolled out so quickly was because the companies weren’t afraid of making the investment with the government fronting the costs. Right now, development is in the works, but still in vitro, which doesn’t tell health officials much about their efficacy.Furthermore, as the CDC has outlined, COVID is moving quickly — likely quicker than the vaccine now.On the bright side, he said the dominance of the delta variant could be working in humanity’s favour since doctors can target delta. That is — until the next thing comes along.Looking ahead, the Johns Hopkins expert said things have moved very rapidly with COVID, from trials to prevention developments, so more clinical trial results will likely be coming out in the next few months, especially because of the increasing number of COVID cases. He said some drugs may be modestly effective, but he doesn’t see any “showstoppers.”Source: nbcmontana.com[MEDIA=youtube]CO8WiGUO008[/MEDIA][MEDIA=youtube]5RWGh19yTXw[/MEDIA]</blockquote>

Verification: Hathara warak wissa keeyada? (Hathara wadi karanna 20)

Top Bottom